Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Hematology/oncology Clinics of North America
Othman Al-SawafKirsten Fischer

Abstract

With the advent of highly effective novel therapies for chronic lymphocytic leukemia, conventional response assessment is not able to sensitively capture depth of response. To achieve a more precise assessment of response, minimal residual disease has been introduced to more accurately classify and quantify treatment outcomes. It is now considered a strong predictor of outcome in chronic lymphocytic leukemia, although its interpretation depends on the therapeutic context. This review discusses available methods of minimal residual disease measurement. It summarizes minimal residual disease data from pivotal clinical trials and discusses potential implications for future studies and minimal residual disease-based clinical strategies.

References

Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian
Feb 9, 2007·Leukemia·V H J van der VeldenUNKNOWN European Study Group on MRD detection in ALL (ESG-MRD-ALL)
Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Dec 14, 2011·Proceedings of the National Academy of Sciences of the United States of America·Aaron C LoganDavid B Miklos
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Jun 21, 2012·Blood·Jennifer A WoyachJohn C Byrd
Apr 9, 2013·Hematology/oncology Clinics of North America·Sebastian BöttcherMichael Kneba
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenChristopher F E Pocock
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Sep 2, 2016·Haematologica·Lieselot Buedts, Peter Vandenberghe
Aug 31, 2017·Current Hematologic Malignancy Reports·Srinivas K TantravahiMichael W Deininger
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
May 13, 2018·Blood·John G Gribben
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.